Haemonetics Corporation (HAE) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $77.20 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single third-party vendor.
Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%) segments, selling automated collection systems, disposables, and software to plasma centers, hospitals, and blood collectors. Top 10 customers represent ~42% of net... Read more
Sell if holding. Analyst target reached at $77.20 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single third-party vendor. Chart setup: Death cross but MACD improving, RSI 76. Score 5.4/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Haemonetics Corporation
Latest news
- NEWS Chiesi strikes $1.9B deal for KalVista and its oral HAE therapy - FirstWord Pharma — FirstWord Pharma positive
- NEWS Haemonetics Earnings: What To Look For From HAE - StockStory — StockStory neutral
- NEWS Haemonetics Earnings: What To Look For From HAE - FinancialContent — FinancialContent neutral
- NEWS NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA - The Globe and Mail — The Globe and Mail neutral
- NEWS Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop-10 customers42%10-K Item 1: 'In fiscal 2025, our ten largest customers accounted for approximately 42% of our net revenues.'
- HIGHSuppliersingle third-party vendor10-K Item 1A: 'we rely on a single vendor to support several of our business processes, including customer service and support and elements of enterprise technology, procurement, accounting and human resources.'
Material Events(8-K, last 90d)
- 2026-05-01Item 5.02LOWDirector Charles J. Dockendorff will not stand for re-election at the 2026 Annual Meeting of Shareholders. Not the result of any disagreement. Will continue serving until the meeting.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $77.20 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single third-party vendor. Chart setup: Death cross but MACD improving, RSI 76. Prior stop was $71.80. Score 5.4/10, moderate confidence.
Take-profit target: $80.35 (+4.1% upside). Prior stop was $71.80. Stop-loss: $71.80.
Concentration risk — Supplier: single third-party vendor; Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.6): -1.0.
Haemonetics Corporation trades at a P/E of 38.1 (forward 13.6). TrendMatrix value score: 5.8/10. Verdict: Sell.
15 analysts cover HAE with a consensus score of 4.1/5. Average price target: $83.
What does Haemonetics Corporation do?Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%)...
Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%) segments, selling automated collection systems, disposables, and software to plasma centers, hospitals, and blood collectors. Top 10 customers represent ~42% of net revenues; the Plasma segment is concentrated among a limited number of large biopharmaceutical customers. Business processes are outsourced to a single third-party vendor.